Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 04 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-1.13 Insider Own24.37% Shs Outstand125.22M Perf Week6.54%
Market Cap147.36M Forward P/E- EPS next Y-1.38 Insider Trans-0.23% Shs Float97.76M Perf Month-0.87%
Income-141.27M PEG- EPS next Q-0.50 Inst Own51.67% Short Float15.95% Perf Quarter9.62%
Sales127.24M P/S1.16 EPS this Y57.29% Inst Trans15.33% Short Ratio3.36 Perf Half Y-66.96%
Book/sh-0.12 P/B- EPS next Y-39.81% ROA-41.58% Short Interest15.59M Perf Year-78.49%
Cash/sh1.31 P/C0.87 EPS next 5Y- ROE-538.57% 52W Range0.91 - 6.87 Perf YTD-18.57%
Dividend Est.- P/FCF- EPS past 5Y-0.93% ROI-74.01% 52W High-83.41% Beta2.27
Dividend TTM- Quick Ratio2.47 Sales past 5Y64.89% Gross Margin88.72% 52W Low25.27% ATR (14)0.09
Dividend Ex-Date- Current Ratio2.71 EPS Y/Y TTM52.19% Oper. Margin-102.89% RSI (14)50.59 Volatility8.84% 6.80%
Employees431 Debt/Eq- Sales Y/Y TTM851.37% Profit Margin-111.03% Recom2.50 Target Price5.05
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q23.83% Payout- Rel Volume1.01 Prev Close1.23
Sales Surprise-79.28% EPS Surprise26.21% Sales Q/Q-91.00% EarningsMar 05 BMO Avg Volume4.64M Price1.14
SMA203.99% SMA50-4.58% SMA200-57.65% Trades Volume4,693,248 Change-7.32%
Date Action Analyst Rating Change Price Target Change
Jun-26-23Resumed Oppenheimer Outperform $12
Apr-21-23Initiated JP Morgan Neutral $7
Jul-23-21Downgrade Goldman Neutral → Sell $24 → $7
May-18-21Resumed Goldman Neutral $24
Mar-05-21Upgrade Chardan Capital Markets Neutral → Buy $30
Sep-18-20Downgrade Chardan Capital Markets Buy → Neutral $32.50 → $27.50
Aug-18-20Initiated Piper Sandler Overweight $40
Aug-11-20Upgrade Jefferies Hold → Buy $4 → $29
Aug-11-20Reiterated H.C. Wainwright Buy $8 → $41
Apr-30-19Initiated Jefferies Hold $7
Feb-28-24 07:00AM
Feb-27-24 07:00AM
Feb-26-24 07:00AM
Jan-17-24 07:00AM
Jan-09-24 08:44AM
07:00AM Loading…
Jan-08-24 06:30AM
Jan-04-24 04:00PM
Dec-07-23 07:46PM
Nov-28-23 09:18AM
Nov-27-23 07:01PM
Nov-21-23 06:00AM
Nov-05-23 02:22PM
Nov-02-23 08:47AM
07:32AM Loading…
Nov-01-23 10:30AM
Oct-30-23 05:30PM
Oct-19-23 10:30AM
Oct-12-23 07:00AM
Oct-06-23 07:00AM
Oct-02-23 07:00AM
Sep-27-23 08:31AM
Sep-11-23 06:30AM
Sep-08-23 07:00AM
Sep-07-23 10:00AM
Aug-29-23 09:00AM
Aug-09-23 06:27AM
Aug-08-23 08:25AM
07:19AM Loading…
Aug-04-23 07:00AM
Aug-01-23 07:00AM
Jul-14-23 04:01PM
Jul-07-23 10:17AM
Jun-21-23 09:00AM
Jun-17-23 03:45PM
Jun-09-23 07:00AM
Jun-05-23 07:00AM
Jun-02-23 07:00AM
May-30-23 04:00PM
May-16-23 06:00AM
May-10-23 07:00AM
May-09-23 08:15AM
May-08-23 07:00AM
May-05-23 07:00AM
Apr-29-23 09:03AM
Apr-27-23 10:03AM
Apr-26-23 07:46PM
Apr-24-23 02:09AM
Apr-20-23 09:45AM
Apr-14-23 05:10AM
Apr-07-23 07:00AM
Apr-04-23 04:30PM
Mar-22-23 03:44AM
Mar-09-23 07:00AM
Mar-08-23 10:45PM
Mar-07-23 10:28PM
Mar-03-23 04:00PM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-14-23 07:00AM
Feb-08-23 07:28AM
Feb-03-23 11:30AM
Jan-28-23 07:51AM
Jan-13-23 07:00AM
Jan-05-23 07:00AM
Jan-04-23 07:00AM
Nov-22-22 04:01PM
Nov-08-22 05:35AM
Nov-02-22 08:35AM
Oct-27-22 07:00AM
Oct-26-22 07:00AM
Oct-23-22 03:30PM
Oct-19-22 02:00PM
Oct-12-22 07:00AM
Sep-22-22 05:51AM
Sep-08-22 07:00AM
Sep-07-22 07:00AM
Aug-29-22 06:43AM
Aug-08-22 06:11AM
Aug-04-22 07:00AM
Aug-03-22 08:15AM
Jul-28-22 07:00AM
Jul-19-22 12:21PM
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shaff Eric D.CEO and PresidentFeb 16Sale1.0811,54912,473135,321Feb 16 09:42 PM
Ege David S.See RemarksFeb 16Sale1.085,0105,41173,856Feb 16 09:15 PM
von Moltke LisaSee RemarksFeb 16Sale1.084,4004,75216,988Feb 16 09:21 PM
Henn Matthew R.See RemarksFeb 16Sale1.084,1704,50463,436Feb 16 09:31 PM
Arkowitz DavidChief Financial OfficerFeb 16Sale1.083,9394,254182,442Feb 16 09:13 PM
DesRosier ThomasChief Legal Officer and EVPFeb 16Sale1.083,9394,254120,577Feb 16 09:48 PM
Young Teresa L.See RemarksFeb 16Sale1.083,3743,64415,705Feb 16 09:29 PM
Shaff Eric D.CEO and PresidentOct 30Sale1.358,55211,545115,620Oct 31 09:40 PM
von Moltke LisaSee RemarksOct 30Sale1.354,2325,7139,513Oct 31 09:36 PM
DesRosier ThomasChief Legal Officer and EVPOct 30Sale1.354,1565,611113,891Oct 31 09:39 PM
Arkowitz DavidChief Financial OfficerOct 30Sale1.354,0665,489175,756Oct 31 09:39 PM
Ege David S.See RemarksOct 30Sale1.354,0665,48966,991Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 30Sale1.353,8865,24656,356Oct 31 09:36 PM
Young Teresa L.See RemarksOct 30Sale1.352,9073,9248,454Oct 31 09:40 PM
Cloghessy PaulaSee RemarksOct 30Sale1.352,9043,92045,684Oct 31 09:43 PM
Cloghessy PaulaSee RemarksOct 27Option Exercise0.009,418048,588Oct 31 09:43 PM
Young Teresa L.See RemarksOct 27Option Exercise0.0011,361011,361Oct 31 09:40 PM
Shaff Eric D.CEO and PresidentOct 27Option Exercise0.0027,8380124,172Oct 31 09:40 PM
Arkowitz DavidChief Financial OfficerOct 27Option Exercise0.0013,2090179,822Oct 31 09:39 PM
Ege David S.See RemarksOct 27Option Exercise0.0011,361071,057Oct 31 09:39 PM
DesRosier ThomasChief Legal Officer and EVPOct 27Option Exercise0.0013,5010118,047Oct 31 09:39 PM
Henn Matthew R.See RemarksOct 27Option Exercise0.0012,623060,242Oct 31 09:36 PM
von Moltke LisaSee RemarksOct 27Option Exercise0.0013,745013,745Oct 31 09:36 PM
Ege David S.See RemarksApr 28Sale5.197,03836,52759,696May 01 04:46 PM